Excellent Survival Outcome in a Patient Receiving NALIRIFOX for Metastatic Pancreatic Adenocarcinoma: A Case Report
{{output}}
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is frequently diagnosed at an advanced stage and remains associated with poor survival outcomes. Durable responses to systemic therapy in metastatic disease are uncommon. We r... ...